NeoRx
Executive Summary
OncoTrac produced by Boehringer lngelheim subsidiary Dr. Karl Thomae GmbH has the same characteristics as those described in a previously filed PLA for the small cell lung cancer monoclonal antibody imaging agent, Seattle-based NeoRx announces Sept. 30. Clinical data from a small-scale study were requested by FDA after NeoRx switched manufacturers of the NR-LU-10 monoclonal antibody used in OncoTrac from lnvitron to B-1 after it had filed a PLA for the product ("The Pink Sheet" June 1, T&G-2). B-1 also must file a new Establishment License Application, which it plans to file by year end, NeoRx says. B-1 will market OncoTrac in the U.S.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth